Skip to main content
TipRanks
Go Ultimate75% OFF

Akebia Therapeutics (AX9) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

AX9 Analyst Ratings

Strong Buy
4Ratings
4Buy0Hold0Sell
Based on 4 analysts giving stock ratings to Akebia Therapeutics in the past 3 months

AX9 Stock 12 Month Forecast

€3.06▲(599.08% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is EUR 3.06 with a high forecast of EUR 4.08 and a low forecast of EUR 1.81. The average price target represents a 599.08% change from the last price of EUR 0.44.
Highest Price Target€4.08Average Price Target€3.06Lowest Price Target€1.81

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:AX9
Price TargetArticle
Piper Sandler€3.63→€1.81buy314.27%UpsideReiterated11/16/26
H.C. Wainwright€5.44→€3.63buy728.54%UpsideReiterated11/06/26
BTIG€3.63→€2.72buy521.40%UpsideReiterated11/05/26
Westpark Capital€4.08buy832.11%UpsideInitiated09/08/26
Leerink Partners€0.91hold107.13%UpsideDowngraded08/07/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OVIDOvid Therapeutics
IMUXImmunic
QUITAchieve Life Sciences
COGTCogent Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Akebia Therapeutics

3 Months
Ed Arce
Ed ArceWestpark Capital
Success Rate8/17 ratings generated profit
47%
Average Return
+7.44%

Copying Ed Arce's trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of +7.44% per trade.

1 Year
Ed Arce
Ed ArceWestpark Capital
Success Rate10/17 ratings generated profit
59%
Average Return
+21.57%

Copying Ed Arce's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +21.57% per trade.

2 Years
Ed Arce
Ed ArceWestpark Capital
Success Rate4/17 ratings generated profit
24%
Average Return
-0.05%

Copying Ed Arce's trades and holding each position for 2 Years would result in 23.53% of your transactions generating a profit, with an average return of -0.05% per trade.

AX9 Analyst Recommendation Trends

02468Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for AX9
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy24666
Buy00000
Hold01110
Sell00000
Strong Sell00000
total25776

In the current month, AX9 has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AX9 average Analyst price target in the past 3 months is 3.06.

AX9 Financial Forecast

€-2€-1.5€-1€-0.5€0Q1 2026Q3 2026Q4 2026
High€-0.04
Consensus€-0.06
Low€-0.09

AX9 Earnings Forecast

Next quarter’s earnings estimate for AX9 is -EUR 0.06 with a range of -EUR 0.09 to -EUR 0.04. The previous quarter’s EPS was -EUR 0.05. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€24.3M€31.3M€38.3M€45.3M€52.3MQ1 2026Q3 2026Q4 2026
High€32.7M
Consensus€29.5M
Low€24.3M

AX9 Sales Forecast

Next quarter’s sales forecast for AX9 is EUR 29.50M with a range of EUR 24.31M to EUR 32.69M. The previous quarter’s sales results were EUR 33.48M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

AX9 Stock Forecast FAQ

What is DE:AX9’s average 12-month price target, according to analysts?
Based on analyst ratings, Akebia Therapeutics’s 12-month average price target is €3.06.
What is DE:AX9’s upside potential, based on the analysts’ average price target?
Akebia Therapeutics has 599.08% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Akebia Therapeutics a Buy, Sell or Hold?
Akebia Therapeutics has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Akebia Therapeutics’s share price target?
The average share price target for Akebia Therapeutics is €3.06. This is based on 4 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €4.08, and the lowest forecast is €1.81. The average share price target represents a 599.08% increase from the current price of €0.438.
What do analysts say about Akebia Therapeutics?
Akebia Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Street analysts.
How can I buy shares of Akebia Therapeutics?
To buy shares of DE:AX9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.